Cytocom, Inc.
CBLI · NASDAQ
6/30/2021 | 3/31/2021 | 12/31/2020 | 9/30/2020 | |
|---|---|---|---|---|
| Market Cap | $85 | $75 | $45 | $26 |
| - Cash | $14 | $14 | $2 | $3 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $71 | $60 | $43 | $23 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | -100% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | 100% | 100% |
| EBITDA | -$1 | -$1 | -$1 | -$1 |
| % Margin | – | – | -263,193,403,868,533.7% | -1,723.6% |
| Net Income | -$1 | -$1 | -$1 | -$1 |
| % Margin | – | – | -264,202,751,937,689.7% | -1,707.8% |
| EPS Diluted | -0.043 | -0.038 | -0.053 | -0.057 |
| % Growth | -12.7% | 29.2% | 6.8% | – |
| Operating Cash Flow | -$1 | -$0 | -$1 | -$1 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$1 | -$0 | -$1 | -$1 |